



6/5/2015

NYSE MKT:LBMH



Company

Liberator Medical Supply Inc. is a wholly owned subsidiary of Liberator Medical Holdings Inc., (NYSE MKT: LBMH). The Company offers over 5,000 products to Medicare-eligible patient populations with chronic conditions requiring repeat orders of maintenance supplies. Direct billing to Medicare is a key component of the Company's strategic plans, providing strong third-party payment revenue continuum, critical to funding the Company's goals, as well as creating continued consumer purchase incentive due to ease and convenience.

The Company's management team, led by founder CEO Mark Libratore, brings a unique competitive advantage to Liberator's goals of rapid expansion into several of the healthcare market's highest-opportunity growth segments. As creators of a marketing model that uses national Direct-to-Consumer advertising to fuel the growth of their former company, Liberty Medical Supply, into a super brand in the diabetes arena, Mr. Libratore and his team are recognized as innovative contributors to the growth of the U.S. medical supplies industry.

By executing their own marketing model to meet four of the highest growth opportunities of the industry--mastectomy, urology, ostomy and mobility patients --as well as diabetes-- the Liberator brand is in a unique position to achieve market leadership and increased long-term value for its shareholders.

Revenue	Q1	Q2	Q3	Q4	Year
2015	\$20.2	\$19.7			
2014	\$18.6	\$17.6	\$18.6	\$19.7	\$74.6
2013	\$17.5	\$16.7	\$17.5	\$17.3	\$69.1
2012	\$14.8	\$14.7	\$15.0	\$16.5	\$60.9
2011	\$12.2	\$12.7	\$13.3	\$14.5	\$52.7

Gross Profit	Q1	Q2	Q3	Q4	Year
2015	\$12.6	\$12.2			
2014	\$11.8	\$11.0	\$11.8	\$12.2	\$46.8
2013	\$11.0	\$10.7	\$10.9	\$10.8	\$43.4
2012	\$8.8	\$9.0	\$9.1	\$10.1	\$37.0
2011	\$7.8	\$7.9	\$8.0	\$8.3	\$32.1

Net Income	Q1	Q2	Q3	Q4	Year
2015	\$2.42	\$1.70			
2014	\$2.12	\$1.61	\$1.98	\$2.09	\$7.80
2013	\$1.35	\$1.42	\$2.01	\$2.29	\$7.08
2012	\$0.45	\$0.67	\$0.68	\$0.70	\$2.50
2011	-\$3.33	\$0.31	\$0.09	\$0.06	\$0.26


Note for Tables: All numbers in millions, Fiscal Year-End September

Investments Highlights

- Leading national direct to consumer provider of Urological, Ostomy, Mastectomy, Diabetes and other medical supplies.
- Proven, highly scalable business model, aggressively expanding into product-line segments targeting chronic conditions resulting in predictable recurring revenue stream with significant customer lifetime values.
- Ranked #1 in Medicare Payments for Urological and Mastectomy Products according to HME Databank.
- An Exemplary Provider™ accredited by The Compliance Team.
- Experienced Management team with over 30+ years of relevant experience and a significant amount of invested capital into the Company.
- The U.S. national healthcare spending is expected to increase by approximately \$2 trillion from \$2.6 trillion in 2010 to \$4.6 trillion in 2020, according to the Centers for Medicare and Medicaid Services ("CMS").
- CMS estimates that the number of Americans over the age of 65 will increase from an estimated 41.1million in 2011 to 54.2 million in 2020.
- The research firm Rand estimates the number of Americans with two or more chronic conditions will increase from 60 to 81 million between the years 2000 and 2020. Currently more than 90 million Americans live with at least one chronic disease.
- CMS estimates that the national expenditures within the DME market will increase by over \$20 billion from \$35.7 billion in 2010 to \$56.8 billion in 2020.
- The number of DME companies with Medicare billings less than \$300,000 has been declining, or consolidating, over the last few years according to HME News, primarily as a result of increased Medicare accreditation and bonding requirements implemented in 2009.

Yearly Results

All numbers in thousands



Quick Facts and Key Ratios

(All numbers in thousands except per share values)

12-Month Trading Price - Low	\$2.30
12-Month Trading Price - High	\$4.15
Closing Price 6-5-15	\$2.60
Dividend Yield 6-5-15	5.00%
Shares Outstanding 5-4-15	53,429
Market Cap.	\$138,380
Enterprise Value	\$133,260
Last Quarter Revenue	\$19,674
Trailing Twelve Month Revenue	\$78,203
Current Assets (Most Recent 10K or 10Q)	\$25,842
Current Liabilities (Most Recent 10K or 10Q)	\$10,702
Current Ratio (Most Recent 10K or 10Q)	2.41
Total Assets (Most Recent 10K or 10Q)	\$57,333
Total Liabilities (Most Recent 10K or 10Q)	\$23,621
Shareholder Equity (Most Recent 10K or 10Q)	\$33,712



Investor Relations Contact:

Gerald Kieft
Wall Street Resources, Inc.
772-219-7525
gkieft@WallStreetResources.net

Disclaimer—This Fact Sheet on Liberator Medical Holdings ("Liberator" or the "Company"), is provided to you without charge as a convenience and for your information only. Whenever we use the term "content", we are referring to any materials, documents, images, graphics, logos, design, audio, video and any other information provided within this document. By merely providing access to this document, we do not warrant or represent, and you should not assume, that the content in this document includes all material information pertaining to Liberator or that such content represents the most current and up-to-date material information that is publicly available with respect to the Company. Information included was current at the time of inclusion, but may be superseded by subsequent disclosures. Whenever we use the term "material information", we mean information relating to the business, operations or securities of Liberator that would reasonably be expected to significantly affect the value of the Company or the common shares of Liberator.